{"count": 3, "results": [{"_id": "38089917", "pmid": 38089917, "pmcid": "PMC10711185", "title": "Metformin: A potential adjunct for treatment of systemic mastocytosis", "journal": "J Allergy Clin Immunol Glob", "authors": ["Butterfield JH", "Bartemes K"], "date": "2023-11-07T00:00:00Z", "doi": "10.1016/j.jacig.2023.100186", "meta_date_publication": "2024 Feb", "meta_volume": "3", "meta_issue": "1", "meta_pages": "100186", "score": 50252.586, "text_hl": "A lower percentage of these @SPECIES_9606 @@@patients@@@ had @<m>DISEASE_Splenomegaly</m> @DISEASE_MESH:D013163 @@@splenomegaly@@@ compared with other groups not treated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, and none of these @SPECIES_9606 @@@patients@@@ developed @GENE_JAK2 @GENE_3717 @@@Janus kinase 2@@@, @GENE_TET2 @GENE_54790 @@@tet methylcytosine dioxygenase 2@@@, or @GENE_SRSF2 @GENE_6427 @@@serine and arginine-rich splicing factor 2@@@ mutations. ", "citations": {"NLM": "Butterfield JH, Bartemes K. Metformin: A potential adjunct for treatment of systemic mastocytosis J Allergy Clin Immunol Glob. 2024 Feb;3(1):100186. PMID: 38089917", "BibTeX": "@article{38089917, title={Metformin: A potential adjunct for treatment of systemic mastocytosis}, author={Butterfield JH and Bartemes K}, journal={J Allergy Clin Immunol Glob}, volume={3}, number={1}, pages={100186}}"}}, {"_id": "35015172", "pmid": 35015172, "title": "Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model.", "journal": "Invest New Drugs", "authors": ["Alves-Silva AB", "Fenerich BA", "Fonseca NP", "Fernandes JC", "Coelho-Silva JL", "Pereira-Martins DA", "Bianco TM", "Scheucher PS", "Rego EM", "Chahud F", "Machado-Neto JA", "Figueiredo-Pontes LL", "Traina F"], "date": "2022-06-01T00:00:00Z", "doi": "10.1007/s10637-022-01212-y", "meta_date_publication": "2022 Jun", "meta_volume": "40", "meta_issue": "3", "meta_pages": "576-585", "score": 50227.04, "text_hl": "We and others previously demonstrated that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ reduced @<m>DISEASE_Splenomegaly</m> @DISEASE_MESH:D013163 @@@splenomegaly@@@ and platelets counts in peripheral blood in @VARIANT_p.V61F_JAK2_human @VARIANT_tmVar:p|SUB|V|61|F;CorrespondingGene:3717;HGVS:p.V61F;CorrespondingGene:3717;VariantGroup:0;CorrespondingSpecies:9606 @@@JAK2V617F@@@ pre-clinical @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@MPN@@@ models, which highlighted the antineoplastic potential of @CHEMICAL_Biguanides @CHEMICAL_MESH:D001645 @@@biguanides@@@ for @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@MPN@@@ treatment. ", "citations": {"NLM": "Alves-Silva AB, Fenerich BA, Fonseca NP, Fernandes JC, Coelho-Silva JL, Pereira-Martins DA, Bianco TM, Scheucher PS, Rego EM, Chahud F, Machado-Neto JA, Figueiredo-Pontes LL, Traina F. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Invest New Drugs. 2022 Jun;40(3):576-585. PMID: 35015172", "BibTeX": "@article{35015172, title={Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model.}, author={Alves-Silva AB and Fenerich BA and Fonseca NP and Fernandes JC and Coelho-Silva JL and Pereira-Martins DA and Bianco TM and Scheucher PS and Rego EM and Chahud F and Machado-Neto JA and Figueiredo-Pontes LL and Traina F}, journal={Invest New Drugs}, volume={40}, number={3}, pages={576-585}}"}}, {"_id": "29472557", "pmid": 29472557, "pmcid": "PMC5833553", "title": "Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms", "journal": "Cell Death Dis", "authors": ["Machado-Neto JA", "Fenerich BA", "Scopim-Ribeiro R", "Eide CA", "Coelho-Silva JL", "Dechandt CRP", "Fernandes JC", "Rodrigues Alves APN", "Scheucher PS", "Simões BP", "Alberici LC", "de Figueiredo Pontes LL", "Tognon CE", "Druker BJ", "Rego EM", "Traina F"], "date": "2018-02-22T00:00:00Z", "doi": "10.1038/s41419-017-0256-4", "meta_date_publication": "2018 Feb 22", "meta_volume": "9", "meta_issue": "3", "meta_pages": "311", "score": 50042.223, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ reduces @<m>DISEASE_Splenomegaly</m> @DISEASE_MESH:D013163 @@@splenomegaly@@@ in @VARIANT_p.V61F_JAK2_human @VARIANT_tmVar:p|SUB|V|61|F;CorrespondingGene:3717;HGVS:p.V61F;CorrespondingGene:3717;VariantGroup:1;OriginalGene:16452;CorrespondingSpecies:10090 @@@Jak2V617F@@@ knockin-induced @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@MPN@@@ @SPECIES_10090 @@@mice@@@.", "citations": {"NLM": "Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Rodrigues Alves APN, Scheucher PS, Simões BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, Traina F. Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms Cell Death Dis. 2018 Feb 22;9(3):311. PMID: 29472557", "BibTeX": "@article{29472557, title={Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms}, author={Machado-Neto JA and Fenerich BA and Scopim-Ribeiro R and Eide CA and Coelho-Silva JL and Dechandt CRP and Fernandes JC and Rodrigues Alves APN and Scheucher PS and Simões BP and Alberici LC and de Figueiredo Pontes LL and Tognon CE and Druker BJ and Rego EM and Traina F}, journal={Cell Death Dis}, volume={9}, number={3}, pages={311}}"}}]}